This study is for women with endometrial cancer. The purpose is to find out if adding a new immunotherapy drug to the usual combination of chemotherapy drugs can lower the chance of your endometrial cancer growing or spreading.
The purpose of this study is to determine at what dose the study drug (ASP1948) is safe and tolerated and how it is processed in the blood of patients with tumors that cannot be removed (unresectable) or has spread (metastasized) to a different part of the body. When the safe dose is identified, it will be used to evaluate if the study treatment causes tumors to shrink in patients.The screening period for this study can take up to 28 days. The treatment period consists of up to 48 weeks of initial treatment, followed by up to 45 weeks of follow up. If you quality and are willing to continue in the re-treatment period (receiving the study drug again), you will be in the study for an additional 48 weeks.
This clinical trial hopes to test the safety and effectiveness of the study drug, pembrolizumab (MK-3475), in combination with chemotherapy, and if this combination will improve survival in women with persistent, recurrent, or metastatic cervical cancer. You may be able to join this study if you are a female at least 18 years of age with persistent, recurrent, or metastatic cervical cancer and have not been treated with systemic chemotherapy, other than chemotherapy that was received with radiation. Participation will be based on specific criteria.
The study duration is estimated at about 2 years, and in some cases may be longer.
This is a Phase II study for women diagnosed with pelvic-only and or vaginal recurrence of endometrial cancer following complete hysterectomy and bilateral salpingo-oophorectomy at the time of initial diagnosis . Patients will be randomized to receive external pelvic radiation for approximately 5 weeks followed by brachytherapy OR external pelvic radiation for approximately 5 weeks plus weekly chemotherapy with cisplatin followed by brachytherapy. The study is designed as a screening study to estimate the benefit on progression-free survival of the addition of cisplatin to external pelvic irradiation, overall survival, side effects and evaluate factors at study entry and from original hysterectomy as potential prognostic factors.
This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.
The objectives of this trial are to find out whether adjuvant chemotherapy (using two other drugs) after chemo-radiation will increase the chances of survival and reduce the risk of tumor recurrence in the pelvis and other places. The risk and severity of side effects and quality of life during and after treatment will also be evaluated and compared. This trial will help the researchers understand the safety and effectiveness of this new treatment regimen for cervical cancer.